newsfilter
← Latest News
GlobeNewswire·

Mesoblast Showcased at ASX Premier Investor Day Event

  • Mesoblast Limited (Nasdaq:MESO; ASX:MSB) was highlighted at the ASX Investor Day in Melbourne during the "Meet the CEO" session.
  • The presentation detailed Mesoblast's transformation into a commercial-stage biotechnology company & its continued Ryoncil growth.
  • Key value-creation priorities include expanding Ryoncil into adult acute graft-versus-host disease & advancing rexlemestrocel-L for chronic low back pain & cardiopulmonary indications.
  • The company plans disciplined capital deployment to support commercial growth & late-stage development programs.
  • Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease.
  • Mesoblast holds over 1,000 granted patents or applications covering its technology, with protection extending through at least 2044.
  • The company maintains manufacturing locations in Australia, the US & Singapore & has established partnerships in Japan, Europe & China.
  • Presentation materials are available via the ASX Investor Day resources page & Mesoblast's investor website.
Company
Mesoblast Limited
Keywords
Australian Stock Exchange:MSB.AX, Mesoblast Limited